On October 17, 2023 Prescient Therapeutics (ASX:PTX) reported that its abstract for the results of a Phase 1b study in T-cell lymphomas has been accepted for poster presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting in December (Press release, Prescient Therapeutics, OCT 17, 2023, View Source;utm_medium=rss&utm_campaign=prescient-to-announce-phase-1b-cancer-trial-results-at-worlds-largest-haematology-conference [SID1234636113]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The meeting is the largest and most comprehensive hematology conference in the world.

Prescient Therapeutics managing director and CEO, Steven Yatomi-Clarke, said, "It is a huge honour to have our abstract presented at the world’s most prestigious haematology conference. This is a validation of the quality and relevance of the clinical data we are generating in T-cell lymphomas, which is an area of unmet clinical need. It is also a testament to the hard work by the Prescient team and our clinical collaborators.

"Prescient looks forward to presenting this data at ASH (Free ASH Whitepaper) and will release this data to the market concurrently."